GlaxoSmithKline’s injectable drug. raxibacumab, has been approved by the US Food and Drug Administration for treating inhalable anthrax. Inhalation of anthrax is seen as a major bioterrorism risk and is caused when people inhale spores of anthrax bacteria.
Raxibacumab has been developed by GSK’s Human Genome Sciences and is a man-made protein that works by mimicking the naturally produced antibodies and blocks the toxins produced by the anthrax bacteria
Source-Medindia